chartexchange

Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics

Pharmaceutical Technology | Oct 20, 2026 6:28 AM EDT

Buying the UK-based biotech will add a siRNA drug candidate with high sales potential to Merck’s portfolio.

Read original article